Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389756 | 1.00 | EGLN3 (1.00) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| SCHEMBL3042066 | 0.90 | EGLN3 (0.82) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| SCHEMBL3795629 | 0.89 | EGLN3 (0.80) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| SCHEMBL6852835 | 0.85 | EGLN3 (0.74) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| SCHEMBL4284704 | 0.85 | EGLN3 (0.74) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| SCHEMBL1035783 | 0.83 | EGLN3 (0.71) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| SCHEMBL28299392 | 0.83 | EGLN3 (0.70) | EGLN3TDP1HTTL3MBTL1APAF1 | |
| Procodazole SCHEMBL7135555 | 0.83 | EGLN3 (0.68) | EGLN3TDP1HTTLMNAKDM4E | |
| SCHEMBL6442808 | 0.82 | TDP1 (1.00) | EGLN3TDP1HTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL17309670 | 0.81 | KDM4E (0.74) | EGLN3TDP1HTTL3MBTL1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171698-A1 | Anti-hypertensive molecules and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH. | 2008-07-17 | — | — | US | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050032709-A1 | Anti-hypertensive molecules and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2005-02-10 | — | — | US | claimed |
| WO-2004087743-A2 | ANTI-HYPERTENSIVE PEPTIDE DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-14 | — | — | WO | claimed |
| JP-57031617-A | — | — | None | — | — | JP | disclosed |
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117242047-A | Process for the vapor phase hydrogenation of aldehydes | 陶氏技术投资有限责任公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-0361069-B1 | Benzimidazole-2-carboxylic-acid anilides, their use as photoprotection composition for organic materials and organic materials stabilised by these anilides | BASF AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
| US-4985566-A | PHOTOSTABILIZERS FOR POLYMERS AND COATINGS | BASF AKTIENGESELLSCHAFT (DE) | 1991-01-15 | — | — | US | disclosed |
| US-4981975-A | PHOTOSTABILITY | BASF AKTIENGESELLSCHAFT (DE) | 1991-01-01 | — | — | US | disclosed |
| EP-0361069-A1 | Benzimidazole-2-carboxylic-acid anilides, their use as photoprotection composition for organic materials and organic materials stabilised by these anilides | BASF Aktiengesellschaft (DE) | 1990-04-04 | — | — | EP | disclosed |
| US-4517188-A | HYPOTENSIVE AGENTS, VASODILATORS, ADRENERGIC BETA BLOCKERS | MEAD JOHNSON & COMPANY (US) | 1985-05-14 | — | — | US | disclosed |
| JP-S5731617-A | CARCINOSTATIC AGENT | NIPPON SHINYAKU CO LTD | 1982-02-20 | — | — | JP | disclosed |
| US-3987054-A | CORROSION INHIBITORS | PLIVA PHARMACEUTICAL AND CHEMICAL WORKS (YU) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171698-A1 | Anti-hypertensive molecules and process for preparation thereof | REN, ACE, AGT | EGLN3 974/4885TDP1 4333/4885HTT 4464/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | EGLN3 1569/4885TDP1 1352/4885HTT 540/4885 |
| US-20050032709-A1 | Anti-hypertensive molecules and process for preparation thereof | AGT, ACE, REN | EGLN3 742/4885TDP1 4029/4885HTT 3631/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | EGLN3 3291/4885TDP1 1008/4885HTT 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.